euro adhoc: other
curasan: US-Registration for REVOIS® Dental Implant System
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
Marketing
12.06.2007
curasan AG (ISIN DE 000 549 453 8) listed in the Prime Standard obtained the FDA-certification for her REVOIS® dental implant system. By this, the medical product is registered for distribution in the United States of America, and the product can be launched ahead of schedule within the ICOI World Congress in San Francisco by end of August 2007, by the company´s own sales organization, curasan Inc.
About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. With the REVOIS® implant system, the company´s sales is focusing more prominently on the growth market of dental surgery/implantology. The majority of new products emerging from the substantial development pipeline are to be offered under licence within other medical fields. Please visit curasan´s corporate website at www.curasan.com
end of announcement euro adhoc 12.06.2007 15:52:04
Further inquiry note:
Dr. Erwin Amashaufer, curasan AG, tel. +49 6027 4686-465, email: ir@curasan.de
Andrea Weidner, curasan AG, tel. +49 6027 4686-467, email: ir@curasan.de
Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade
Original content of: Curasan AG, transmitted by news aktuell